Member news

Autolus Therapeutics plc, an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the National Institute for Health and Care Excellence (NICE) has published draft guidance recommending AUCATZYL® (obecabtagene autoleucel, or “obe-cel”) for use in the National Health Service (NHS) in England and Wales as a treatment option for adult patients (≥26 years) with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL).

eXmoor Pharma, the integrated cell and gene therapy CDMO with embedded consultancy expertise, and Royal Free London NHS Foundation Trust, through its Cell and Vector Innovation Centre (CVIC), have entered a strategic collaboration to build a seamless, scalable pathway for cell and gene therapy development and manufacturing in the UK.

Novo Nordisk announced the submission of a sNDA to the U.S. Food and Drug Administration (FDA) for a higher dose of semaglutide injection 7.2 mg, to be used along with a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity. Under the CNPV expedited program, review is expected within 1–2 months following the FDA’s acceptance of the filing.

Sai Life Sciences, Agility Life Sciences, and Centrix Pharma Solutions announce an ‘Integrated CMC Partnership’ to accelerate drug development for innovators.

Senior leaders from PHTA and Clinical Immunology Services took home the top prizes in two prestigious categories at the West Midlands Innovation Awards

The Functional Genomics Screening Laboratory, based at the Milner Therapeutics Institute, has won an OBN Award in the category of Most Impactful Industry Collaboration.

GLP-1 collaboration to support value-based reimbursement models for GLP-1 receptor agonists, optimizing patient outcomes, increasing markets, and healthcare sustainability.

Macomics Ltd, a leader in macrophage drug discovery, announces that it has validated its ENIGMAC™ platform in macrophage mediated antifibrotic therapy.

Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed a search assignment for Slingshot Therapeutics Limited and is pleased to announce the placement of Dr John Isaac as Chief Scientific Officer.

Constructive Bio and RxCelerate have formed a strategic partnership to develop novel biologic therapeutic candidates targeting multiple disease indications, including liver fibrosis and other cardiometabolic diseases. Combining Constructive Bio’s pioneering programmable biology platform with RxCelerate’s expert drug design and development capabilities to drive innovation in engineered biologics for challenging diseases.

T-Therapeutics, a biotechnology company developing next-generation T cell receptor (TCR) therapeutics for cancer and autoimmune disease, today announces the successful expansion of its Series A financing, raising afurther $32 million. Following the initial $59 million raised, this brings the Series A total to date to $91 million.

The British Business Bank has announced a €30 million commitment to Sofinnova Partners (Sofinnova) new €650 million ($750 million) fund, Sofinnova Capital XI. 

The UK’s used nuclear materials will be recycled to create an evergreen supply of new precision cancer medicines, offering hope for patients with previously untreatable cancers.

Prokarium appoints Ibs Mahmood as Chief Executive Officer

Oxford-based techbio startup Scripta Therapeutics emerges from stealth by announcing a $12 million seed round to upend conventional approaches to drug discovery. Scripta combines AI, imaging, and patient-derived models to create and modulate disease maps based on transcriptional networks, building a new biology-first paradigm to decode and undo the programs that drive disease. The round is led jointly by Oxford Science Enterprises (OSE) and Apollo Health Ventures, with further investment from AlbionVC, YZR Capital, and Parkwalk Advisors, and support from Oxford University Innovation.

PIR International recently partnered with a PE-backed pharmaceutical services company in appointing a Chief Growth Officer.

LinkGevity's first-in-class Anti-Necrotic drug was featured in the Sunday Express this week. The article highlights the transformative potential of targeting necrosis- a long-overlooked driver of age-related degeneration.

The novel assay, developed with GenScript’s THE™ His Tag Monoclonal Antibodies, provides researchers with a ready-to-use solution for rapid, reliable measurement of His-tagged proteins.

The Medical Research Council, Wellcome Trust, and Innovate UK have today announced a major new £15.9 million initiative to enable the development of advanced, specific and highly reproducible human-based in vitro models of disease, to make them widely available to researchers in academia and industry.

MyAmici, a leading provider of LabOps solutions for biotech and life science organisations, is pleased to announce its strategic entry into the Swiss market through a partnership with Kisco Pharma Outsourcing Solutions. This collaboration marks a significant milestone in MyAmici’s European expansion and brings together two complementary organisations committed to empowering scientific innovation.